Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP001: Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn’s and Colitis Organisation studyECCO '18 Vienna
Year: 2018
Authors:

U. Kopylov1*, B. Verstockt2, L. Biedermann3, S. Sebastian4, D. Pugliese5, E. Sonnenberg6, P.R. Steinhagen6, N. Arebi7, Y. Ron8, T. Kucharzik9, X. Roblin10, B. Ungar1, A. Bar-Gil Shitrit11, S. Ardizzone12, P. Molander13, M. Coletta14, L. Peyrin-Biroulet15, P. Bossuyt16, I. Avni-Biron17, E.I. Tsoukal18, M. Allocca19, K. Katsanos20, T. Raine21, T. Sipponen22, G. Fiorino23, S. Ben-Horin1, R. Eliakim1, A. Armuzzi5, B. Siegmund6, D.C. Baumgart6, N. Kamperidis7, N. Maharshak8, C. Maaser9, G. Mantzaris18, H. Yanai17, D. Christodoulou20, I. Dotan17, M. Ferrante2

1Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 2KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3University of Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, 4Hull Royal Infirmary, Hull and East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, UK, 5IBD Unit, Complesso Integrato Columbus, Fondazione Policlinico Gemelli, Università Cattolica, internal Medicine, Gastroenterology Division, Rome, Italy, 6Charité - University Hospital Berlin, Campus Benjamin Franklin, Department of Gastroenterology and Medicine I, Berlin, Germany, 7LNWH ST MARKS HOSPITAL, Harrow, UK, 8Tel Aviv Medical Ceter, IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel, 9Hospital Lüneburg, Department of Internal Medicine and Gastroenterology, Lüneburg, Germany, 10CHU de Saint-Etienne, Gastroenterology, Saint-Etiennne, France, 11Shaare Zedek Medical Center, Digestive diseases Institute, Jerusalem, Israel, 12ASST Fatebenefratelli - Sacco, Milan, Italy, 13Helsinki University Central Hospital, Department of Gastroenterology, Department of Medicine, Helsinki, Finland, 14Department of Pathophysiology and Transplantation, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy, Gatroenterology, Milan, Italy, 15Nancy University Hospital, Université de Lorraine, Hepatogastroenterology, Vandoeuvre-lès-Nancy, France, 16Imelda GI Clinical Research Center, Gastroenterology, Bonheiden, Belgium, 17Rabin Medical Center, Department of Gastroenterology and Liver Diseases, Petach Tikva, Israel, 18Evaggelismos Hospital, Gastroenterology, Athens, Greece, 19Humanitas Gradenigo, Gastroenterology, Turin, Italy, 20University of Ioannina, Gastroenterology, Ioannina, Greece, 21Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, Cambridge, UK, 22Helsinki University Central Hospital - Meilahti Hospital, Department of Gastroenterology, Helsinki, Finland, 23Humanitas Research Hospital, Department of Gastroenterology, IBD Center, Rozzano, Italy

DOP002: Vedolizumab treatment persistence up to 3 years: post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS studyECCO '18 Vienna
Year: 2018
Authors:

S. Vermeire1*, E.V. Loftus Jr.2, J.M. Khalid3, D. Tudor4, M. Akbari5, D. Demuth3, L. Peyrin-Biroulet6

1University Hospitals Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium, 2Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, Minnesota, USA, 3Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK, 4Takeda Pharmaceuticals International AG, Zurich, Switzerland, 5Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA, 6Nancy University Hospital, Lorraine University, Department of Gastroenterology, Nancy, France

DOP003: Ustekinumab induces clinical and biological remission in biologic refractory Crohn’s disease patients: A real-world belgian cohort studyECCO '18 Vienna
Year: 2018
Authors:

C. Liefferinckx1,2*, B. Verstockt3, A. Gils4, M. Noman3, C. Van Kemseke5, E. Macken6, M. De Vos7, W. Van Moerkercke8, J.-F. Rahier9, P. Bossuyt10, J. Dutré11, E. Humblet12, D. Staessen13, H. Peeters14, P. Van Hootegem15, E. Louis5, D. Franchimont1,2, F. Baert16, S. Vermeire3

1Hopital Erasme, ULB, Department of Gastroenterology, Brussels, Belgium, 2Université libre de bruxelles, Laboratory of Experimental Gastroenterology, Brussels, Belgium, 3University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 4KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 5Centre Hospitalier Universitaire Sart-Tilman, ULG, Department of Gastroenterology, Liège, Belgium, 6Universiteit ziekenhuis Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, 7Universitair ziekenhuis Gent, Department of Gastroenterology, Gent, Belgium, 8AZ Groeninge, department of Gastroenterology, Kortrijk, Belgium, 9Centre Hospitalier Universitaire Mont-Godinne, UCL, Department of Gastroenterology, Yvoir, Belgium, 10Imeldaziekenhuis, Department of Gastroenterology, Bonheiden, Belgium, 11Ziekenhuis Netwerk Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, 12Ziekenhuis Oost-Limburg - Campus Sint-Jan, Department of Gastroenterology, Genk, Belgium, 13GZA Sint-Vincentius ziekenhuis, Department of Gastroenterology, Antwerpen, Belgium, 14Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Gent, Belgium, 15Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Brugge, Belgium, 16AZ Delta, Department of gastroenterology, Roeselare-Menen, Belgium

DOP004: Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACYECCO '18 Vienna
Year: 2018
Authors:

P. Bossuyt1*, R. Atreya2, C. Taxonera3,4, X. Hebuterne5,6, K. Isaacs7, P.D. Higgins8, J. Lindsay9, G. Heap10, D. Arikan10, V. Kuehnl11, J. Petersson10, A.M. Robinson10, E.V. Loftus Jr.12

1Imelda General Hospital, Bonheiden, Belgium, 2Friedrich-Alexander-University Erlangen-Nürnberg, Medical Clinic 1, Erlangen, Germany, 3Hospital Clínico San Carlos, Inflammatory Bowel Disease Unit, Department of Gastroenterology, Madrid, Spain, 4Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, 5Service de Gastroentérologie et Nutrition Clinique, Nice, France, 6Université de Nice-Sophia-Antipolis, Nice, France, 7University of North Carolina, Division of Gastroenterology and Hepatology, Chapel Hill, USA, 8University of Michigan, Ann Arbor, USA, 9Queen Mary University of London, Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, London, UK, 10AbbVie Inc., North Chicago, USA, 11AbbVie Deutschland GmbH and Co. KG, Ludwigshafen, Germany, 12Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, USA

DOP005: Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonistsECCO '18 Vienna
Year: 2018
Authors:

R. Cohen1, F. Bhayat2*, G. Hantsbarger2, A. Blake3, S. Vermeire4

1Inflammatory Bowel Disease Center, University of Chicago Medicine, Department of Medicine, Chicago, USA, 2Takeda Development Center Americas, Inc., Cambridge, USA, 3Takeda International - UK Branch, London, UK, 4University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium

DOP006: A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

J. Meserve1, S. Aniwan2, J.L. Koliani-Pace3, P. Shashi4, A. Weiss5, D. Faleck6, A. Winters6, S. Chablaney6, G. Kochhar4, B. Boland1, S. Singh1, R. Hirten6, E. Shmidt6, M. Bohm7, S. V Sagi7, M. Fischer7, D. Lukin5, D. Hudesman8, S. Chang8, K. Sultan9, A. Swaminath10, N. Gupta11, S. Kane2, E.V. Loftus2, B. Shen4, B.E. Sands6, J.-F. Colombel6, C.A. Siegel3, W.J. Sandborn1, P.S. Dulai1*

1University of California - San Diego, La Jolla, USA, 2Mayo Clinic, Rochester, USA, 3Dartmouth-Hitchcock Medical Center, Lebanon, USA, 4Cleveland Clinic Foundation, Cleveland, USA, 5Montefiore Medical Center, New York, USA, 6Icahn School of Medicine at Mount Sinai, New York, USA, 7Indiana University, Indianapolis, USA, 8New York University (NYU), New York, USA, 9North Shore University Hospital, Manhasset, USA, 10Lenox Hill Hospital, New York, USA, 11University of Mississippi, Jackson, USA

DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

R. Bor1*, F. Klaudia2, P. Miheller3, K. Palatka4, T. Szamosi5, Á. Vincze6, M. Rutka7, K. Szántó2, A. Bálint2, Z. Szepes2, F. Nagy2, Á. Milassin2, A. Fábián2, Á. Csontos3, P. Golovics5, L. Lakner8, K. Müllner3, M. Papp9, Á. Salamon10, K. Sarang8, Z. Vitális4, E. Schafer11, P. Sarlós6, T. Molnár2

1University of Szeged, First Department of Medicine, Szaged, Hungary, 2University of Szeged, First Department of Medicine, Szeged, Hungary, 3Semmelweis University, 2nd Department of Medicine, Budapest, Hungary, 4University of Debrecen, 2nd Department of Medicine, Debrecen, Hungary, 5Hungarian Defence Force Military Hospital, Department of Gastroenterology, Budapest, Hungary, 6University of Pécs, 1st Department of Medicine, Pécs, Hungary, 7Uversity of Szeged, First Department of Medicine, Szeged, Hungary, 8Markusovszky Teaching Hospital, Szombathely, Hungary, 9University of Debrecen, 2nd Department of Medicine, Szeged, Hungary, 10Balassa János Hospital, Szekszárd, Hungary, 11Semmelweis University, 2nd Department of Medicine, Szeged, Hungary

DOP008: Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registryECCO '18 Vienna
Year: 2018
Authors:

D. Turner1*, S. Koletzko2, H. Winter3, R. Baldassano4, M. Dubinsky5, W. Faubion6, J. Hyams7, S. Kugathasan8, J. Rosh9, J. Escher10, A. Griffiths11, J. Kierkus12, R. Russell13, G. Heap14, D. Arikan14, V. Kuehnl15, J. Petersson14, A. Robinson16, F. Ruemmele17

1Institute of Pediatric Gastroenterology, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Jerusalem, Israel, 2Dr. von Hauner Children’s Hospital, University Medical Center, LMU Munich, Munich, Germany, 3Department of Pediatrics, Massachusetts General Hospital, Boston, USA, 4Pediatric Gastroenterology, The Children’s Hospital of Philadelphia, Philadelphia, USA, 5Department of Pediatrics, Division of Gastroenterology, Mount Sinai Medical Center, New York, USA, 6Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, USA, 7Division of Digestive Diseases, Connecticut Children’s Medical Center, Hartford, USA, 8Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, USA, 9Division of Gastroenterology and Nutrition, Goryeb Children’s Hospital, Morristown, USA, 10Erasmus Medical Center-Sophia Children’s Hospital, Rotterdam, The Netherlands, 11Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada, 12Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Children’s Memorial Health Institute, Warsaw, Poland, 13Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, UK, 14AbbVie Inc., North Chicago, USA, 15AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 16Abbvie, Inc., North Chicago, USA, 17Paediatric Gastroenterology, Hôpital Necker Enfants Malades, APHP, University Paris Descartes Sorbonne Paris Cité, Paris, France

DOP009: Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysisECCO '18 Vienna
Year: 2018
Authors:

D. Lukin1, A. Weiss1, S. Aniwan2, S. Kadire3, G. Tran3, M. Rahal3, D. Faleck4, A. Winters4, S. Chablaney4, J. Meserve5, G. Kochhar6, P. Shashi6, J.L. Koliani-Pace7, M. Bohm3, S.V. Sagi3, M. Fischer3, B. Boland5, S. Singh5, R. Hirten4, E. Shmidt4, D. Hudesman8, S. Chang8, K. Sultan9, A. Swaminath10, N. Gupta11, S. Kane2, E.V. Loftus2, B. Shen6, B.E. Sands4, W.J. Sandborn5, J.-F. Colombel4, C.A. Siegel7, P.S. Dulai5*

1Montefiore Medical Center, New York, USA, 2Mayo Clinic, Rochester, USA, 3Indiana University, Indianapolis, USA, 4Icahn School of Medicine at Mount Sinai, New York, USA, 5University of California - San Diego, La Jolla, USA, 6Cleveland Clinic Foundation, Cleveland, USA, 7Dartmouth-Hitchcock Medical Center, Lebanon, USA, 8New York University (NYU), New York, USA, 9North Shore University Hospital, Manhasset, USA, 10Lenox Hill Hospital, New York, USA, 11University of Mississippi, Jackson, USA

DOP010: Activating PIK3CD mutations cause severe intestinal lymphonodular hyperplasia and an IBD-like phenotypeECCO '18 Vienna
Year: 2018
Authors:

S. Farachi1, L. Werner2, L. Konnikova3, F. Rea1, I. Vardi4, E. Romeo1, O. Barel4, P. De Angelis1, L. Dall’Oglio1, G. Rechavi4, S. Snapper3, R. Somech2, B. Weiss5, C. Cancrini1, D. Shouval2*

1Bambino Gesù Children Hospital, Department of Endoscopy, Rome, Italy, 2Edmond and Lily Safra Children's Hospital, Pediatric Gastroenterology Unit, Tel Hashomer, Israel, 3Boston Children's Hospital, Boston, USA, 4Sheba Medical Center, Tel Hashomer, Israel, 5Edmond and Lily Safra Children's Hospital, Tel Hashomer, Israel

DOP011: Genotype–phenotype association analysis of inflammatory bowel disease in 6395 East Asian subjects: results from the international IBD Genetics ConsortiumECCO '18 Vienna
Year: 2018
Authors:

S. Abedian1*, S.H. Wong2, S. Van Sommeren3, A. Takahashi4, J.H. Cheon5, W.H. Kim5, K. Yamazaki6, S.-K. Yang7, M. Kubo6, R.K. Weersma3, B.Z. Alizadeh1, S.C. Ng2

1University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands, 2The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Faculty of Medicine, Hong Kong, China, 3University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands, 4Riken, Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, Yokohama, Japan, 5Yonsei University College of Medicine, Department of Gastroenterology and Hepatology, Seoul, South Korea, 6Riken, Laboratory for Genotyping Development, Center for Integrative Medical Sciences, Yokohama, Japan, 7Asan Medical Center, University of Ulsan College of Medicine, Department of Gastroenterology and Hepatology, Seoul, South Korea

DOP012: Disease demarcation in ulcerative colitis is associated with different patterns of gene expressionECCO '18 Vienna
Year: 2018
Authors:

M. Suarez-Farinas1, R. Huang1, R. Kosoy1, A. Irizar1, B. Losic1, G. Wei1, L. Peters1, W.-m. Song1, A. Di Narzo1, W. Wang1, J. Perrigoue2, A. Castillo3, J. Rogers3, A. Atreja3, A. Hurley1, M. Mahajan1, B. Zhang1, A. Stojmirovic2, M. Curran2, R. Dobrin2,4, M. Dubinsky3, K. Hao1, J. Zhu1, E. Schadt1, S. Plevy2, J. Friedman2, C. Brodmerkel2, B. Sands3, A. Kasarskis1, R. Ungaro3, C. Argmann1*, J.-F. Colombel3

1Icahn School of Medicine at Mount Sinai, Genetics and Genomics Sciences, New York, USA, 2Janssen R&D, Spring House, USA, 3Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, USA, 4Bristo-Myers Squibb, Hopewell, USA

DOP013: An IBD-associated variant in PTPN2 promotes inflammatory responses but enhances the anti-inflammatory effect of spermidineECCO '18 Vienna
Year: 2018
Authors:

M. Butter*, N. Obialo, K. Bäbler, L. Van der Lely, S. Lang, C. Gottier, M. Scharl, M.R. Spalinger

University Hospital of Zurich, University of Zurich, Clinic for Gastroenterology and Hepatology, Zurich, Switzerland

DOP014: Impact of genetic variation on gene and protein expression in Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

A. Hart*, K. Hayden, E. Wadman, S. Bhagat, D. Jacobstein, C. Brodmerkel, J. Friedman, K. Li

Janssen Research & Development, LLC, Spring House, USA

DOP015: Dysregulation of cell-type-specific long ncRNA in the ileum of treatment naïve early onset Crohn diseaseECCO '18 Vienna
Year: 2018
Authors:

Y. Haberman1,2*, M. BenShoshan1, A. Di Segni1, P.J. Dexheimer3, T. Braun1, B. Weiss1, C. Avivi1, I. Barshack1, Y. Anikster1, B. Aronow3, J.S. Hyams4, S. Kugathasan5, L.A. Denson3, The Crohn's & Colitis Foundation (CCF)-sponsored RISK study

1Sheba Medical Center, Tel Hashomer, Israel, 2CCHMC, Cincinnati, USA, 3Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, 4Connecticut Children’s Medical Center, Hartford, USA, 5Emory University, Atlanta, USA

DOP016: Metagenomic analysis of intestinal mucosa revealed an IBD-specific shift in the eukaryotic gut virome composition at early stages of gut inflammationECCO '18 Vienna
Year: 2018
Authors:

F. Ungaro1*, L. Massimino2, S. D'Alessio1, S. Danese1

1Humanitas University, Biomedical Science, Milan, Italy, 2San Raffaele Scientific Institute, Division of Neuroscience, Milan, Italy

DOP017: Increased intestinal aryl hydrocarbon receptor expression and pathway sensitivity in Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

P. Harrow1,2*, N. McCarthy1, A. Stagg1, J. Lindsay1,2

1Blizard Institute, Immunobiology, London, UK, 2Royal London Hospital, Gastroenterology, London, UK

DOP018: Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

B. Creyns1*, B. Verstockt2,3, J. Cremer1, M. Ferrante2,3, S. Vermeire2,3, C. Jan1, G. Van Assche2,3, C. Breynaert1

1KULeuven, Lab of Clinical Immunology, Leuven, Belgium, 2University Hospital Gasthuisberg, Department of Gastroenterology, Leuven, Belgium, 3KU Leuven, TARGID - Department of Chronic Diseases, Metabolism and Aging, Leuven, Belgium

DOP019: Immunomodulators reduce the risk of surgery and hospitalisation in Crohn’s disease in a prospective European population-based inception cohort: the Epi-IBD cohortECCO '18 Vienna
Year: 2018
Authors:

J. Burisch1*, V. Andersen2,3, S. Čuković-Čavka4, P.L. Lakatos5, R. D'Inca6, F. Magro7,8,9, N. Arebi10, L. Kievit11, I. Kaimakliotis12, D. Valpiani13, K.H. Katsanos14, Z. Vegh5, J.F. Dahlerup15, M. Fumery16, N. Pedersen17, J. Halfvarson18, E. Belousova19, K.R. Nielsen20, S. Turcan21, P. Ellul22, L. Kupcinskas23, P. Oksanen24, D. Duricova25, M. Giannotta26, A. Goldis27, V. Hernandez28, R. Salupere29, S. Odes30, E. Langholz31, P. Munkholm1, Epi-IBD study group

1North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark, 2Viborg Regional Hospital, Medical Department, Viborg, Denmark, 3Hospital of Southern Jutland, Medical Department, Aabenraa, Denmark, 4University Hospital Center Zagreb, University of Zagreb School of Medicine, Division of Gastroenterology and Hepatology, Zagreb, Croatia, 5Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 6Azienda Ospedaliera di Padova, Department of Surgery, Oncology and Gastroenterology, Padova, Italy, 7University of Porto, Institute for molecular and cell biology, Porto, Portugal, 8Hospital de São João, Department of Gastroenterology, Porto, Portugal, 9Oporto Medical School, Institute of Pharmacology and Therapeutics, Porto, Portugal, 10St Mark's Hospital, Gastroenterology, London, UK, 11Herning Central Hospital, Department of medicine, Herning, Denmark, 12Nicosia Private practice, Nicosia Private practice, Nicosia, Cyprus, 13Department of Gastroenterology and Digestive Endoscopy, Morgagni Hospital, Forli, Italy, 14University Hospital, Ioannina, 1st Division of Internal Medicine and Hepato-Gastroenterology Unit, Ioannina, Greece, 15Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark, 16Amiens University and Hospital, Epimad Registry, Gastroenterology Unit, Amiens, France, 17Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark, 18Faculty of Medicine and Health, Örebro University, Department of Gastronterology, Örebro, Sweden, 19Moscow Regional Research Clinical Institute, Department of Gastroenterology, Moscow, Russian Federation, 20The National Hospital of the Faroe Islands, Medical department, Tórshavn, Faroe Islands, 21State University of Medicine and Pharmacy of the Republic of Moldova, Department of Gastroenterology, Chisinau, Moldova, Republic of, 22Mater Dei Hospital, Division of Gastroenterology, L-Imsida, Malta, 23Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania, 24Tampere University Hospital, Department of Gastroenterology and Alimentary Tract Surgery, Tampere, Finland, 25Charles University, IBD Center ISCARE, Prague, Czech Republic, 26AOU Careggi Regional Referral Center for Inflammatory Bowel Disease, Gastroenterology Department, Florence, Italy, 27University of Medicine ‘Victor Babes’, Clinic of Gastroenterology, Timisoara, Romania, 28Complexo Hospitalario Universitario de Vigo, Gastroenterology Department, Vigo, Spain, 29Tartu University Hospital, Division of Endocrinology and Gastroenterology, Tartu, Estonia, 30Soroka Medical Center and Ben Gurion University of the Negev, Department of Gastroenterology and Hepatology, Beer Sheva, Israel, 31Gentofte Hospital, Department of Medical Gastroenterology, Copenhagen, Denmark

DOP020: Thiopurine monotherapy still has a place in the treatment of patients with mild-to-moderate Crohn’s disease in the biological eraECCO '18 Vienna
Year: 2018
Authors:

B. Verstockt1,2*, L. Boets1, G. Van Assche1,2, S. Vermeire1,2, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium